ライフサイエンスコーパス: N-hydroxysuccinimide

1 ive was significantly improved using DCC and N-hydroxysuccinimide.

2 acid on Au(111) in the presence of EDAC and N-hydroxysuccinimide.

3 hemical cross-linking using carbodiimide and N-hydroxysuccinimide.

4 -dimethylaminopropyl)-carbodiimide and sulfo-N-hydroxysuccinimide.

5 lf-molecule was covalently radiolabeled with N-hydroxysuccinimide [(3)H]methotrexate.

6 tivity 99mTc-S-acetylmercaptoacetyltriserine-N-hydroxysuccinimide ([99mTc-MAS3]-NHS) prepared by soli

7 lizing the antibody for the biomarkers on an N-hydroxysuccinimide activated 16-mercaptohexadecanoic a

8 activated glycans were covalently printed on N-hydroxysuccinimide-activated glass slides and interrog

9 N-Hydroxysuccinimide active ester 15, a key common inter

10 g the carboxyl groups to the active ester of N-hydroxysuccinimide; and (iii) incorporating a charge s

11 ropyl)carbodiimide as the coupling agent and N-hydroxysuccinimide as activator.

12 ohols with Ru(+2) complexes as catalysts and N-hydroxysuccinimide as oxidant, which requires formatio

13 -1 derivatized with a long chain form of the N-hydroxysuccinimide biotin (NHS-biotin) to yield N(alph

14 ylated with cell-impermeable reagents, sulfo-N-hydroxysuccinimide-biotin and sulfo-N-hydroxysuccinimi

15 Docking studies and N-hydroxysuccinimide-biotin binding studies support a pr

16 S exposure in normal red cell aging, we used N-hydroxysuccinimide-biotin to tag rabbit red cells in v

17 re labeled with the impermeant reagent sulfo-N-hydroxysuccinimide-biotin, both PrPC and PrPSc were fo

18 olate conjugate was prepared by employing an N-hydroxysuccinimide/carbodiimide method.

19 l-3-(3-dimethylaminopropyl)-carbodiimide and N-Hydroxysuccinimide coupling reagents, in electrochemic

20 ethylamino)propyl]carbodiimide hydrochloride/N-hydroxysuccinimide coupling.

21 cterized the ability of DIDS and of selected N-hydroxysuccinimide cross-linking agents to increase th

22 n of N-tosylaziridines and reprotection with N-hydroxysuccinimide derivatives is described.

23 dine deprotection step, while acylation with N-hydroxysuccinimide derivatives is highly efficient.

24 of ethyl(dimethylaminopropyl)carbodiimide / N-hydroxysuccinimide (EDC/NHS) between the amine group p

25 3-(3-(dimethylamino)propyl)-carbodiimide and N-hydroxysuccinimide (EDC/NHS) chemistry.

26 -N'-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide (EDC/NHS) chemistry.

27 using 3-(3-dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide (EDC/NHS) coupling to carboxylic ac

28 l-3-(3-dimethylaminopropyl) and carbodiimide/N-hydroxysuccinimide (EDC/NHS) was adopted to improve th

29 ded Tregs using biotin-poly(ethylene glycol)-N-hydroxysuccinimide ester (biotin-PEG-NHS) and streptav

30 ctrodes using 3,3'-dithiodipropionic acid di(N-hydroxysuccinimide ester (DTSP) as a self-assembled mo

31 opropyl-triethoxysilane (3-APTES) and biotin-N-hydroxysuccinimide ester (NHS-biotin).

32 , followed by reaction with TMPP-acetic acid N-hydroxysuccinimide ester (TMPP-AcOSu bromide, 2-4 nmol

33 Here, we show that m-maleimidobenzoyl-N-hydroxysuccinimide ester and 1,5-difluoro-2, 4-dinitro

34 inking of PDE subunits with maleimidobenzoyl-N-hydroxysuccinimide ester and para-phenyldimaleimide.

35 face coated with alkenes functionalized with N-hydroxysuccinimide ester groups resulted in the covale

36 H conjugate prepared with m-maleimidobenzoyl-N-hydroxysuccinimide ester linker, plus QS-21, has been

37 otein content of 4 mg/mL, the use of a novel N-hydroxysuccinimide ester of 16-mercaptohexadecanoic ac

38 er92 (alpha 83-92) were derivatized with the N-hydroxysuccinimide ester of 4-azidobenzoylglycine (ABG

39 onyldiimidazole, followed by coupling of the N-hydroxysuccinimide ester of CBZ-protected L- or D-thre

40 Anti-oxLDL was conjugated with the N-hydroxysuccinimide ester of DOTA (1,4,7,10-tetraazacyc

41 The peptide was conjugated with the N-hydroxysuccinimide ester of mercaptoacetyltriglycine (

42 is reported involving derivatization with an N-hydroxysuccinimide ester of N-alkylnicotinic acid (Cn-

43 sing size were produced by reaction with the N-hydroxysuccinimide ester of polyethylene glycol-5000 (

44 Cross-linking by the maleimidobenzoyl-N-hydroxysuccinimide ester of the peripheral membrane fr

45 veloped by incorporation of methacrylic acid N-hydroxysuccinimide ester or 2-aminoethyl methacrylate

46 ally enriched N-methylpiperazine acetic acid N-hydroxysuccinimide ester reagents, it was found that t

47 c sites (nucleophiles) unreactive toward the N-hydroxysuccinimide ester reagents, resulting in sites

48 o-phenylenedimaleimide or m-maleimidobenzoyl-N-hydroxysuccinimide ester showed that the binding of Ca

49 The N-hydroxysuccinimide ester surface acted as a template f

50 ed, buffered reactions with formylmethionine-N-hydroxysuccinimide ester to model 11 amino acid nucleo

51 igated and 3-(2-pyridyldithio)propionic acid N-hydroxysuccinimide ester was found as the optimal cros

52 modified with 3,3'-dithiodipropionic acid di(N-hydroxysuccinimide ester) to which polyethylene imine

53 -hydroxysuccinimide ester), suberic acid bis(N-hydroxysuccinimide ester), disuccinimidyl tartrate, an

54 midyl iodo-acetate, suberic acid bis(3-sulfo-N-hydroxysuccinimide ester), suberic acid bis(N-hydroxys

55 tively derivatize the free hydrazide with an N-hydroxysuccinimide ester, while the A2pm side-chain am

56 plate by immobilizing Abeta oligomers onto a N-hydroxysuccinimide ester-activated solid surface.

57 Treatment of Golgi membranes with N-hydroxysuccinimide ester-based cross-linking reagents

58 osite by the bio-linker 1-pyrenebutyric acid N-hydroxysuccinimide ester.

59 ps or to make an activated ligand such as an N-hydroxysuccinimide ester.

60 4,6-trimethoxyphenyl)phosphonium acetic acid N-hydroxysuccinimide esters (1 and 2) were synthesized a

61 This too can be a difficult task because N-hydroxysuccinimide esters are not stable in protic sol

62 with 4 different amine-directed agents: the N-hydroxysuccinimide esters of hydrazinonicotinic acid,

63 Further, an N-hydroxysuccinimide-functionalized derivative enabled c

64 atives with terminal amine, carboxylate, and N-hydroxysuccinimide groups suitable for derivatization

65 assay campaign, we investigated a family of N-hydroxysuccinimide inhibitors grounded upon structure

66 D2B was conjugated with N-hydroxysuccinimide-IRDye800CW and p-isothiocyanatobenz

67 cation of the enzyme with acetylphenylalanyl-N-hydroxysuccinimide is nonexistent in the case of the n

68 of the release rate for IgG biotinylated by N-hydroxysuccinimide-LC-biotin.

69 more favorable than those linked through an N-hydroxysuccinimide linkage.

70 with MORF, whereas cMORF was conjugated with N-hydroxysuccinimide-mercaptoacetyltriglycine (MAG3) to

71 By co-expression and N-hydroxysuccinimide methotrexate (Mtx) radioaffinity la

72 treatment with leucovorin, and inhibition by N-hydroxysuccinimide methotrexate, a documented affinity

73 x3) and (iii) lysyl conjugation of 5kDa PEG-N-hydroxysuccinimide (NHS) ester (Co-hArgI-K(PEG-5K)).

74 l S-protection and which is derivitized with N-hydroxysuccinimide (NHS) ester for conjugation, has be

75 riched 4-(dimethylamino)benzoic acid (DMABA) N-hydroxysuccinimide (NHS) ester reagents was developed

76 o a chemically pure complex, with a reactive N-hydroxysuccinimide (NHS) ester, in neat organic solven

77 Sta(13)]-BN(6-14)NH2 (HZ219) with IRDye 650 N-hydroxysuccinimide (NHS) ester.

78 N-Hydroxysuccinimide (NHS) esters are widely used as lea

79 via ion/ion reactions is demonstrated using N-hydroxysuccinimide (NHS) esters as the modifying reage

80 esidues were modified by isothiocyanates and N-hydroxysuccinimide (NHS) esters in a substrate-depende

81 ion to unprotonated arginine side-chains via N-hydroxysuccinimide (NHS) esters is demonstrated throug

82 s was 92% to 98% efficient and conversion to N-hydroxysuccinimide (NHS) esters more than 99%; esters

83 opropyl)carbodiimide (EDC), and treated with N-hydroxysuccinimide (NHS) to improve the biocompatibili

84 for a range of oxygen nucleophiles including N-hydroxysuccinimide (NHS), pentafluorophenol (PFP), hex

85 ent studies used radioaffinity labeling with N-hydroxysuccinimide (NHS)-[(3)H]methotrexate (MTX) to l

86 We covalently conjugated GDAPs to N-hydroxysuccinimide (NHS)-activated glass slides, malei

87 a polyacrylamide coating prepared by bonding N-hydroxysuccinimide (NHS)-activated poly(acrylic acid)

88 selectively captured using a photocleavable N-hydroxysuccinimide (NHS)-biotin linker and streptavidi

89 lized by classic carbodiimide chemistry with N-hydroxysuccinimide (NHS).

90 n azurin with the fluorescent label ATTO 655-N-hydroxysuccinimide(NHS)-ester and fractionated the sam

91 eved using a selective covalent label, sulfo-N-hydroxysuccinimide (NHSA).

92 This was followed by acylation with N-hydroxysuccinimide p-aminosalicylic acid to form the f

93 y primary amine groups in the gas phase with N-hydroxysuccinimide reagents opens up the possibility o

94 yl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide revealed that carboxylate residues

95 ased by 16-19% using EDC combined with sulfo-N-hydroxysuccinimide (s-NHS), and by 17-33% using CMPI.

96 sulfo-N-hydroxysuccinimide-biotin and sulfo-N-hydroxysuccinimide-S-S-biotin in the absence and prese

97 Cross-linking the cell surface proteins with N-hydroxysuccinimide-SS-biotin followed by affinity prec

98 reaction with a self-assembled monolayer of N-hydroxysuccinimide thioctic ester, followed by incorpo

99 The labeling agent is preactivated with N-hydroxysuccinimide to react with primary amines to for